Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NTLABullishIndustry Newsnews

High materiality7/10

Intellia to Highlight Nex-z ATTRv-PN Cardiac Outcomes at AHA and ISA Meetings

Nov 3, 2026, 8:13 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive conference data often nudges biotech stocks higher on potential proof-of-concept signals and durability in Phase 1/2, especially for novel gene-editing assets; however, the data are early-stage and outcomes are not guaranteed, limiting scope to a catalyst-driven move.

AI summary

What happened, with direct paths to the underlying reporting

Intellia will present Nex-z Phase 1 data for ATTRv-PN at two conferences in November, including up to four years of follow-up at ISA. Early cardiac-outcome signals and durability could bolster near-term sentiment around NTLA's ATTR program and broader CRISPR initiatives, though data are still early-stage and outcomes remain uncertain.

NTLA to present Nex-z cardiac outcomes in ATTRv-PN at AHA on Nov 9.
ISA presentation on Nov 18 will include up to four years of follow-up data.
Phase 1 Nex-z data may influence NTLA's ATTR program valuation.
Longer follow-up data could improve safety/efficacy confidence.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Intellia to Highlight Nex-z ATTRv-PN Cardiac Outcomes at AHA and ISA Meetings

Intellia's lonvo-z HAE data bolster 2H2026 BLA path

Intellia's Crispr Treatment Shows Promising Efficacy in Late-Stage Trial

FDA Clears Clinical Hold on Intellia's Gene Therapy Trial

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder